Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 25, Issue 2, 2010, Pages 158-171

  Garofalo, Antonio ^a   Goossens, Laurence ^a   Lemoine, Amelie ^a   Farce, Amaury ^a   Arlot, Yannick ^b   Depreux, Patrick ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Cancer; EGFR; Inhibitors; Prostate; Quinazoline; VEGFR

Indexed keywords

AMIDE; CARBAMIC ACID DERIVATIVE; ETHYL [4 (6,7 DIMETHOXY QUINAZOLIN 4 YLAMINO)PHENYL]CARBAMATE; ETHYL [4 [7 (2 DIETHYLAMINOETHOXY) 6 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL]CARBAMATE HYDROCHLORIDE; METHYL [4 (6,7 DIMETHOXY QUINAZOLIN 4 YLAMINO)PHENYL]CARBAMATE; METHYL [4 [6 (2 DIETHYLAMINOETHOXY) 7 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL]CARBAMATE HYDROCHLORIDE; METHYL [4 [7 (2 DIETHYLAMINOETHOXY) 6 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL]CARBAMATE HYDROCHLORIDE; N CYCLOHEXYL N' [4 (6,7 DIMETHOXY QUINAZOLIN 4 YLAMINO)PHENYL]UREA; N CYCLOHEXYL N' [4 [7 (2 DIETHYLAMINOETHOXY) 6 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL]UREA HYDROCHLORIDE; N [4 (6,7 DIMETHOXY QUINAZOLIN 4 YLAMINO)PHENYL] N' (2,4 DIFLUOROPHENYL)UREA; N [4 (6,7 DIMETHOXY QUINAZOLIN 4 YLAMINO)PHENYL] N' (3 CHLORO 4 FLUOROPHENYL)UREA; N [4 (6,7 DIMETHOXY QUINAZOLIN 4 YLAMINO)PHENYL] N' (4 METHOXYPHENYL)UREA; N [4 (6,7 DIMETHOXY QUINAZOLIN 4 YLAMINO)PHENYL] N' BUTYLUREA; N [4 (6,7 DIMETHOXY QUINAZOLIN 4 YLAMINO)PHENYL] N' ETHYLUREA; N [4 (6,7 DIMETHOXY QUINAZOLIN 4 YLAMINO)PHENYL] N' PHENYLUREA; N [4 (6,7 DIMETHOXY QUINAZOLIN 4 YLAMINO)PHENYL]ACETAMIDE; N [4 [6 (2 DIETHYLAMINOETHOXY) 7 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL] N' (4 METHOXYPHENYL)UREA HYDROCHLORIDE; N [4 [6 (2 DIETHYLAMINOETHOXY) 7 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL] N' PHENYLUREA HYDROCHLORIDE; N [4 [6 (2 DIETHYLAMINOETHOXY) 7 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL]ACETAMIDE HYDROCHLORIDE; N [4 [7 (2 DIETHYLAMINOETHOXY) 6 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL] N' (2,4 DIFLUOROPHENYL)UREA HYDROCHLORIDE; N [4 [7 (2 DIETHYLAMINOETHOXY) 6 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL] N' (3 CHLORO 4 FLUOROPHENYL)UREA HYDROCHLORIDE; N [4 [7 (2 DIETHYLAMINOETHOXY) 6 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL] N' (4 METHOXYPHENYL)UREA HYDROCHLORIDE; N [4 [7 (2 DIETHYLAMINOETHOXY) 6 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL] N' BUTYLUREA HYDROCHLORIDE; N [4 [7 (2 DIETHYLAMINOETHOXY) 6 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL] N' ETHYLUREA HYDROCHLORIDE; N [4 [7 (2 DIETHYLAMINOETHOXY) 6 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL] N' PHENYLUREA HYDROCHLORIDE; N [4 [7 (2 DIETHYLAMINOETHOXY) 6 METHOXY QUINAZOLIN 4 YLAMINO]PHENYL]ACETAMIDE HYDROCHLORIDE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 77949437037     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756360903169485     Document Type: Conference Paper

References (42)

1. Berry PA, Maitland NJ, Collins AT. Androgen receptor signalling in prostate. Effects of factors on normal and cancer stem cells. Mol Cell Endocrinol 2008;288:30-37
2. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
3. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc Chem Res 2003;36:462-469
4. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499-512.
5. Cohen P. The role of protein phosphorylation in human health and disease. Eur J Biochem 2001;268:5001-5010
6. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase as targets for anticancer drugs. Trends Mol Med 2002;8:17-22.
7. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) in signalling in cancer. Gene 2006;366:2-16.
8. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1-11.
9. Ratan HL, Gescher A, Steward WP, Mellon JK. ErbB receptors: possible therapeutic targets in prostate cancer? BJU Int 2003;92:890-895
10. Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res 2006;83:1005-1016
11. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007;19:2003-2012
12. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248
13. Pandaya NM, Dhalla NS, Santani DD. Angiogenesis - a new target for future therapy. Vasc Pharmacol 2006;44:265-274
14. Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 2008;76:15-22.
15. Semino CE, Kamm RD, Lauffenburger DA. Autocrine EGF receptor activation mediates endothelial cell migration and vascular morphogenesis induced by VEGF under interstitial flow. Exp Cell Res 2006;312:289-298
16. Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85:584-589
17. Barton J, Blackledge G, Wakeling A. Growth factor and their receptors: new targets for prostate cancer therapy. Urology 2001;58:114-122
18. Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 2008;34:37-48.
19. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetenz J, et al. Protein kinases as targets for anticancer agents: from inhibitor to useful drugs. Pharmacol Ther 2002;93:79-98.
20. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, et al. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 1999;42:5369-5389
21. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinase as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 1999;82:207-218
22. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10:784-793
23. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Boffey R, et al. ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis and tumor growth following oral administration. Cancer Res 2002;62; 4645-4655
24. Kubo K, Shimizu T, Ohyama S, Murooka H, Iwai A, Nakamura K, et al. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships and antitumor activities of N-phenyl-N'{4-(4-quinolyloxy)phenyl}ureas. J Med Chem 2005;48:1359-1366
25. Dai Y, Hartandi K, Soni NB, Pease LJ, Reuter DR, Olson AM, et al. Identification of aminopyrazolopyridine ureas as potent VEGFR/ PDGFR multitargeted kinase inhibitors. Bioorg Med Chem Lett 2008;18:386-390
26. Frey RR, Curtin ML, Albert DH, Glaser KB, Pease LJ, Soni NB, et al. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. J Med Chem 2008;51:3777-3787
27. Bouey-Bencteux E, Loison C, Pommery N, Houssin R, Hénichart JP. Synthesis and antiproliferative properties of 4-aminoquinazoline derivatives as inhibitors of EGF receptor-associated tyrosine kinase activity. Anticancer Drug Des 1998;13:893-922.
28. Desroses M, Laconde G, Telliez A, Piron MC, Pommery N, Depreux P, et al. Development of new anilinoquinazolines, potentially inhibitor of the tyrosine kinase activity of the EGF receptor. Fund Clin Pharmacol 2004;18:593-599
29. Telliez A, Desroses M, Pommery N, Briand O, Farce A, Laconde G, et al. Derivatives of Iressa, a specific epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells. ChemMedChem 2007;2:318-332
30. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose- Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-267
31. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, et al. Studies leading to the identification of ZD1839 (Iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem 2001;11:1911-1914
32. Barber HJ, Washboum K, Wragg R, Lunt E. A new cinnoline synthesis. Cyclisation of mesoxalyl chloride phenylhydrazones to give substituted 4-hydroxycinnoline-3-carboxylic acids. J Chem Soc 1961;28:28-43.
33. SYBYL 6.9.1. St. Louis, MO: Tripos Inc.
34. Clark M, Crammer RD III, Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. J Comput Chem 1989;10:982-1012.
35. Berman HM, Westbrook J, Feng Z, Gary G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000;28:235-242
36. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265-46272
37. Miyazaki Y, Matsunaga S, Tang J, Maeda Y, Nakano M, Philippe RJ, et al. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg Med Chem Lett 2005;15:2203-2207
38. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748
39. Wang R, Lai L, Wang S. Further development and validation empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des 2002;16:11-26.
40. Desroses M, Laconde G, Depreux P, Hénichart JP. Synthesis of unsymmetrical dialkoxy quinazolines. Org Prep Proc Int 2004;36:445-452
41. Furuta T, Sakai T, Senga T, Osawa T, Kubo K, Shimizu T, et al. Identification of potent and selective inhibitors of PDGF receptor autophosphorylation. J Med Chem 2006;49:2186-2192
42. Elliott RD, Thomas HJ, Shaddix SC, Adamson DJ, Brockman RW, Riordan JM, et al. Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis. J Med Chem 1988;31:250-254